New news off sedarTaken from sedar - SASKATOON, Saskatchewan--(BUSINESS WIRE)--February 22, 2017--CanniMed Therapeutics Inc. (TSX: CMED) proactively commissioned an independent laboratory analysis of the Companys herbal cannabis products to test for 56 known pesticides, fungicides and PGRs (plant growth regulators). Each analyzed lot returned a clean Certificate of Analysis with not detected levels for each of the 56 pesticides, fungicides and PGRs. CanniMed Therapeutics has never, and will not in the future need to use pesticides, fungicides or PGRs in the manufacturing of our medical cannabis products because we follow a strict GMP process, following 281-points of quality control, said Brent Zettl, President and CEO, CanniMed Therapeutics Inc. By commissioning this evaluation, we looked to demonstrate to patients, physicians and investors how our GMP-compliant production process ensures cleanliness and prevention, resulting in products that can be trusted to be free from all contaminants. CMED commissioned Anandia Labs, Canadas leading cannabis genetics and testing facility founded by internationally-recognized cannabis scientist Dr. Jonathan Page for this important analysis. Four lots of CMEDs proprietary strains (CanniMed 22.1, CanniMed 12.0, CanniMed 9.9 and CanniMed 1 .13) were analyzed and each were awarded a clean Certificate of Analysis. Anandia Labs uses highly sensitive LC-MS/MS methods to identify and quantify the main pesticides and PGRs of known concern in cannabis, including myclobutanil, bifenazate and paclobutrazol, said Dr. Jonathan Page, President and CEO, Anandia Labs. Our lab has been at the forefront of cannabisrelevant pesticide testing and I am pleased that Anandia Labs was chosen by a leading Licensed Producer such as CanniMed Therapeutics to provide independent testing services to help ensure patient safety.